Bli medlem
Bli medlem

Du är här


Bionor Pharma ASA: Bionor Pharma ASA - Notice of Extraordinary General Meeting 7 November 2016



Notice of Extraordinary General Meeting 7 November 2016

(Oslo, Norway, 14 October 2016) An Extraordinary General Meeting of Bionor
Pharma ASA will be held on Monday 7 November 2016 at 16:30 hours at KS Agenda
Møtesenter, Haakon VIIs gate 9 in Oslo, Norway.

Due to the recent issuance of new shares in the private placement and the
rights offering the current authorization to the Board to issue new shares is
in the view of the board insufficient. The Board finds it necessary that the
company has flexibility to issue new shares on short notice in order to be
able to obtain additional funding for the Company, strategic measures and/or
future operations. The Board accordingly call the EGM to propose to the
shareholders to resolve a new authorization to the Board to issue shares in
the Company.

The notice of the Extraordinary General Meeting on 7 November 2016 is
attached hereto and includes detailed registration and proxy instructions.

All relevant documents and link to online registration of attendance and
advance voting can be found

Please note that to attend the Extraordinary General Meeting, attendants must
be registered shareholders five working days prior to the meeting - 31
October 2016.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651,

About Bionor
Bionor Pharma's mission is to enable the immune system to fight HIV infection.
Bionor is the first company, which has successfully completed a clinical
trial using the shock and kill approach, thereby creating a strong foundation
for further advancing its therapeutic vaccine Vacc-4x in combination with
other agents towards a functional cure. The company believes it has first
mover potential based on clinical results to date and early adoption of the
shock and kill strategy. In December 2015, Bionor announced that the HIV
trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint
by reducing latent HIV reservoir and further demonstrated control of viral
load. Bionor currently retains full ownership rights to the HIV immunotherapy
Vacc-4x, i.e., the upside potential from partnering or licensing remains with
the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More
information about Bionor is available



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.